Vaxcyte (PCVX)
(Real Time Quote from BATS)
$33.00 USD
-0.02 (-0.06%)
Updated Aug 4, 2025 09:46 AM ET
3-Hold of 5 3
D Value F Growth C Momentum F VGM
Fundamental Charts
About Market Cap
As of the previous market close, Vaxcyte, Inc. has a market cap of $4.26B, which represents its share price of $33.02 multiplied by its outstanding shares number of 129.00M. As a mid-cap company, PCVX's shareholders are generally exposed to less risk than shareholders of small-cap companies but more risk than large-cap companies.
The company's Market Capitalization is a measurement of company size. It is calculation of the company's share price times the number of outstanding shares. Large market cap companies give stability and are good long-term investments. Small market cap companies can produce faster growth and bigger returns, but their stockholders are exposed to more risk.
PCVX 33.00 -0.02(-0.06%)
Will PCVX be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for PCVX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for PCVX
Vaxcyte Stock Plummets 56% in a Month: Here's the Reason
Biotech Stocks Fall After Top FDA Official Quits Over Clash With RFK Jr.
PCVX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Merck Gets EC Nod for 21-Valent Pneumococcal Jab Capvaxive
MRK Gets Positive CHMP Nod for 21-Valent Pneumococcal Jab Capvaxive
Sanofi's 21-Valent Pneumococcal Vaccine Enters Phase III
Other News for PCVX
RA CAPITAL MANAGEMENT, L.P. Acquires 2,122,000 Shares in Contineum Therapeutics Inc
TimesSquare U.S. Small Cap Growth Strategy Q2 2025 Commentary
RA CAPITAL MANAGEMENT, L.P. Increases Stake in Vor Biopharma Inc.
Vaxcyte (PCVX) Maintains Strength Amid Potential Vaccine Review | PCVX Stock News
Vaxcyte vaccine candidates contain aluminum, says Mizuho